Cochrane review questions real-world benefits of anti-amyloid Alzheimer's drugs
A new Cochrane analysis of 17 trials (over 20,000 participants) finds amyloid-beta–targeting monoclonal antibodies, including Leqembi and Kisunla, likely confer little to no meaningful cognitive or functional benefit in mild cognitive impairment or mild Alzheimer's, while modestly increasing the risk of ARIA-E (brain swelling); despite some trial-specific benefits for individual drugs, the overall class effect is in doubt, prompting calls to pursue other disease mechanisms.